A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Irinotecan (Primary) ; Veliparib (Primary)
- Indications Breast cancer; Cervical cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 19 May 2017 Status changed from suspended to recruiting.
- 21 Sep 2016 Status changed from recruiting to suspended due to drug supply issues
- 19 Jul 2016 Status changed from not yet recruiting to recruiting.